| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Endogenous metabolite (Deuterated internal standard)
|
|---|---|
| ln Vitro |
The compound is a deuterium-labeled purine analogue, serving as an analytical standard. Hypoxanthine is a purine derivative that serves as an intermediate in purine metabolism and a potential free radical generator that can be used as an indicator of hypoxia.
|
| ln Vivo |
Not applicable - The compound is a stable isotope-labeled internal standard with no intrinsic biological activity beyond its role as a tracer. Unlabeled hypoxanthine is a clinically useful biomarker for birth asphyxia and global hypoxic events.
|
| Enzyme Assay |
Not applicable. The compound is characterized by LC-MS/MS, with purity >98% and isotopic enrichment confirmed by mass spectrometry. It is used to construct standard curves for quantifying hypoxanthine in biological fluids without enzyme or receptor assays.
|
| Cell Assay |
For cellular assays, hypoxanthine can be used as a substrate in the salvage pathway of purine nucleotide synthesis. Hypoxanthine-d2 is used as an internal standard for quantifying hypoxanthine levels in cell culture media or lysates during studies of purine metabolism and oxidative stress.
|
| Animal Protocol |
Hypoxanthine-d2 is not administered in animal studies. Instead, unlabeled hypoxanthine is used for biomarker studies. Hypoxanthine accumulates in tissues during hypoxia due to ATP depletion. Studies typically measure hypoxanthine in blood or CSF from animal models of ischemia or hypoxia.
|
| ADME/Pharmacokinetics |
The compound is not evaluated for PK as a drug. Endogenous hypoxanthine has a short half-life, being rapidly converted to xanthine and uric acid by xanthine oxidase. Its accumulation reflects the balance between ATP degradation and clearance.
|
| Toxicity/Toxicokinetics |
Hypoxanthine-d2 has minimal toxicity at analytical concentrations. Unlabeled hypoxanthine is an endogenous metabolite; high levels can contribute to oxidative stress through xanthine oxidase-mediated production of superoxide and uric acid.
|
| References | |
| Additional Infomation |
Hypoxanthine-d2 is an analytical reference material for LC-MS/MS method development and studies of purine metabolism. It is not a drug and has no clinical approval. It is used for research in hypoxia biomarkers and metabolic diseases.
|
| Molecular Formula |
C5H4N4O
|
|---|---|
| Molecular Weight |
136.111459732056
|
| Exact Mass |
138.051
|
| CAS # |
697807-02-6
|
| Related CAS # |
Hypoxanthine;68-94-0
|
| PubChem CID |
57636748
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
-1.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
10
|
| Complexity |
190
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1N=C([H])NC2N=C([H])NC1=2
|
| InChi Key |
FDGQSTZJBFJUBT-QDNHWIQGSA-N
|
| InChi Code |
InChI=1S/C5H4N4O/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)/i1D,2D
|
| Chemical Name |
2,8-dideuterio-3,7-dihydropurin-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.3470 mL | 36.7350 mL | 73.4700 mL | |
| 5 mM | 1.4694 mL | 7.3470 mL | 14.6940 mL | |
| 10 mM | 0.7347 mL | 3.6735 mL | 7.3470 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
